Infergen Market Report 2026

Infergen Market Overview

• The Infergen market growth in the historic period has been driven by high global hepatitis c prevalence, early reliance on interferon therapies • Market expansion is supported by shift toward direct acting antivirals, niche demand in resistant cases • Growth Driver: Rising Chronic Hepatitis C Prevalence Fuels Demand For Infergen Treatment Solutions • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Infergen Market?

Infergen (Interferon alfacon-1) is a recombinant type-I interferon used primarily for the treatment of chronic hepatitis C virus infection in adults with compensated liver disease. It is a synthetic form of interferon that is produced using genetically modified Escherichia coli bacteria, designed to mimic the natural interferons found in the human body. The main patient demographics for infergen are pediatric patients, adult patients, and high-risk groups. Pediatric patients refer to individuals who are in the age group of infancy to adolescence, typically under 18 years of age.Infergen (interferon alfacon-1) is used in pediatric patients to treat chronic hepatitis C, where it works by stimulating the immune system to fight the virus and reduce liver damage. It has applications in chronic hepatitis c treatment and combination therapy and is distributed through channels such as hospitals, specialty clinics, online pharmacies, and pharmacies.

What Is The Infergen Market Growth Forecast?

The growth in the forecast period can be attributed to shift toward direct acting antivirals, niche demand in resistant cases, improved hepatitis screening programs, liver disease management focus, declining interferon dependency. Major trends in the forecast period include declining use of interferon based therapies, selective use in treatment resistant patients, combination therapy optimization, focus on viral load suppression, monitoring of long term liver outcomes.

Global Infergen Market Segmentation

1) By Patient Demographics: Pediatric Patients, Adult Patients, High-Risk Groups 2) By Application: Chronic Hepatitis C Treatment, Combination Therapy 3) By Distribution Channel: Hospitals, Specialty Clinics, Online Pharmacies, Pharmacies

What Are The Drivers Of The Infergen Market?

The rising prevalence of chronic hepatitis C is expected to drive the growth of the infergen market going forward. Chronic hepatitis C is a long-lasting infection caused by the hepatitis C virus, characterized by the persistence of the virus in the body for more than six months, which can lead to serious health complications such as liver damage, cirrhosis, and liver cancer if left untreated. The growing prevalence of chronic hepatitis C is largely attributed to increased rates of injection drug use, which facilitates blood-to-blood transmission of the virus, as well as inadequate access to prevention and treatment services. Infergen, a pegylated form of interferon alfa-2b, helps chronic hepatitis C patients by stimulating the immune system to fight the virus, thereby improving liver function, reducing viral load, and potentially leading to sustained virologic response (SVR), which is crucial for preventing liver damage and complications associated with the disease. For instance, in April 2025, according to the European Centre for Disease Prevention and Control (ECDC), a Europe-based agency for strengthening defenses against infectious diseases, in 2023, 28622 cases of hepatitis C were reported in 29 EU/EEA countries, corresponding to a crude rate of 7.4 cases per 100 000 populations. Further, among the cases reported, 4.9% were acute, 34.1% chronic, and 53.8% were unknown. Therefore, the rising prevalence of chronic hepatitis C is driving the growth of the infergen industry. The rising demand for personalized medicine is expected to significantly drive the growth of the infergen market. Personalized medicine involves customizing medical treatments to align with the unique characteristics, needs, and preferences of each patient, often informed by their genetic makeup, and aims to enhance treatment effectiveness while minimizing adverse effects by considering individual variations in genetics, environment, and lifestyle. The growing demand for personalized medicine is fueled by patients' desire for more effective healthcare solutions that are tailored to their individual genetic, physiological, and lifestyle factors. Infergen (interferon alfacon-1) is used as a personalized medicine by tailoring treatment regimens to individual patient factors, such as viral load and genotype, in chronic hepatitis C. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based organization that represents scientists, patients, and providers, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, an increase from six approvals in 2022. Therefore, the rising demand for personalized medicine is expected to drive the expansion of the infergen industry. The global expansion of healthcare infrastructure is anticipated to significantly boost the growth of infergen in the coming years. Healthcare infrastructure refers to the physical and organizational structures, facilities, resources, and systems that are necessary for delivering healthcare services to a population. The global expansion of healthcare infrastructure is driven by several key factors, including the aging global population, the increase in chronic diseases, and technological advancements. Healthcare infrastructure supports infergen by providing the necessary medical facilities, skilled healthcare professionals, diagnostic tools, and treatment protocols that enable the effective administration of the drug, monitoring of patient progress, and management of potential side effects, ensuring optimal outcomes for patients with chronic hepatitis C. For instance, in April 2025, according to the Office for National Statistics, a UK-based government agency, the UK healthcare expenditure was approximately US$414 billion (£317 billion) in 2024. Further, between 2023 and 2024, total healthcare expenditure grew by 6.5% in nominal terms. Therefore, the global expansion of healthcare infrastructure drives the growth of the infergen industry.

Key Players In The Global Infergen Market

Major companies operating in the infergen market are Amgen Inc.

Regional Insights

North America was the largest region in the infergen market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Infergen Market?

The infergen market includes sales of interferon alfacon-1 injection products available in single-use vials containing 9 mcg and 15 mcg formulations, and combination therapy kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Infergen Market Report 2026?

The infergen market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the infergen industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.